Tuesday 9th November 2021
7:00pm - 9:00pm
Long-acting Injectable Buprenorphine (LAIB) is a formulation of buprenorphine pharmacotherapy that has the promise to be a true game-changer in the area of Medication-Assisted Treatment of Opioid Dependence.
The proven safety record of buprenorphine, combined with a weekly to monthly dosing schedule provide very good reasons for both patients and prescribing clinicians to engage with this new treatment.
At the end of this evening’s presentation, attendees will be able to:
- compare and contrast the effectiveness of long-acting injectable buprenorphine (LAIB) to sublingual buprenorphine and oral methadone in a harm minimisation setting
- outline the indications for treatment, as well as patient-centred factors that would make them less suited for treatment with long-acting injectable buprenorphine
- describe the legal and logistic considerations for LAIB therapy including examples of how these are practically addressed
- demonstrate best practice administration of both Buvidal and Sublocade formulations of LAIB.
RACGP Activity ID#303094 - 4 CPD points